| Name | Cvs Pharmacy #08546 |
|---|---|
| Organization Name | Iowa Cvs Pharmacy Llc |
| Location | 205 Franklin St, Waterloo, Iowa 50703 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (319) 234-4736 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine researchers.
Many think of social networks in terms of Facebook friends and Twitter followers, but for recent University of Georgia doctoral graduate Julie Rushmore, social networks are tools in the fight against infectious diseases.
Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
› Verified 2 days ago
| NPI Number | 1124069034 |
| Organization Name | IOWA CVS PHARMACY LLC |
| Doing Business As | CVS PHARMACY # 08546 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 207 Franklin St, Waterloo, IA 50703 |
| Phone Number | 319-234-4736 |
News Archive
The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine researchers.
Many think of social networks in terms of Facebook friends and Twitter followers, but for recent University of Georgia doctoral graduate Julie Rushmore, social networks are tools in the fight against infectious diseases.
Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
› Verified 2 days ago
News Archive
The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine researchers.
Many think of social networks in terms of Facebook friends and Twitter followers, but for recent University of Georgia doctoral graduate Julie Rushmore, social networks are tools in the fight against infectious diseases.
Acura Pharmaceuticals, Inc. today reported a second quarter 2010 net loss of $3.2 million or $0.07 per share compared to net loss of $6.5 million, or $0.14 per share for the second quarter of 2009. For the six months ended June 30, 2010, the Company reported a net loss of $7.2 million, or $0.15 per share compared to net loss of $7.8 million, or $0.17 per share for the same period in 2009. At July 29, 2010 we had cash and cash equivalents of approximately $26.5 million with no term indebtedness.
Halozyme Therapeutics, Inc. today announced the completion of its root cause investigation regarding HYLENEX manufacturing and has identified a corrective action plan and regulatory strategy to reintroduce HYLENEX to the market. Halozyme and Baxter are finalizing the materials for a meeting with the U.S. Food and Drug Administration to seek concurrence with the reintroduction strategy.
› Verified 2 days ago
Cedar Valley Medical Specialists, P Type: Durable Medical Equipment & Medical Supplies Supplier Location: 909 E San Marnan Dr, Waterloo, Iowa 50702 Phone: (319) 234-2020 | |
Clark & Assoc Prosthetics And Ortho Type: Prosthetic/Orthotic Supplier Location: 527 Park Ln 100, Waterloo, Iowa 50702 Phone: (319) 233-8911 | |
Mercyone Waterloo Home Medical Equi Type: Durable Medical Equipment & Medical Supplies Supplier Location: 441 E San Marnan Dr, Waterloo, Iowa 50702 Phone: (319) 272-5626 | |
Greenwood Drug On Kimball Avenue Type: Compounding Pharmacy Location: 2104 Kimball Avenue, Waterloo, Iowa 50702 Phone: (319) 236-8067 | |
Hanger Prosthetics & Orthotics East Type: Durable Medical Equipment & Medical Supplies Supplier Location: 3825 W 9th St, Waterloo, Iowa 50702 Phone: (319) 234-4010 |